Yonhap Infomax NewsFeb 4
PharmaResearch shares plunged over 10% after a Q4 earnings miss, with the stock now down more than 40% from its 52-week high amid growth concerns.
#YonhapInfomax #PharmaResearch #EarningsMiss #OperatingProfit #NextTrade #52WeekHigh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103832
PharmaResearch Plunges 10% on Earnings Miss—Shares Down Over 40% from 52-Week High

PharmaResearch shares plunged over 10% after a Q4 earnings miss, with the stock now down more than 40% from its 52-week high amid growth concerns.

Yonhap Infomax
Ilya Khodov LabNov 20
Our latest paper on etoricoxib conformational analysis is out! We combined NOESY spectroscopy and quantum-chemical calculations to explore polymorph screening and solvate formation. This research sheds light on the drug's solid-state behavior, crucial for improving pharmaceutical development. Check it out: https://doi.org/10.1016/j.molliq.2025.128897 #PharmaResearch #MolecularLiquids #Etoricoxib #NMR
Yonhap Infomax NewsJul 10, 2025
Shareholder activism platform ACT, after prompting PharmaResearch to abandon a controversial spin-off, is now targeting Hana Micron’s similar plan, signaling a broader push for shareholder rights in South Korea’s capital markets.
#YonhapInfomax #ShareholderActivism #PharmaResearch #HanaMicron #SpinOff #ShareholderValue #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=71548
Shareholder Activism Platform ACT Shifts Focus to Hana Micron After Forcing PharmaResearch to Scrap Spin-Off Plan

Shareholder activism platform ACT, after prompting PharmaResearch to abandon a controversial spin-off, is now targeting Hana Micron’s similar plan, signaling a broader push for shareholder rights in South Korea’s capital markets.

Yonhap Infomax
Yonhap Infomax NewsJul 4, 2025
PharmaResearch Co. has denied tunneling allegations in its dealings with Pixelity, asserting that all transactions were fair and market-based, but investor skepticism persists amid ongoing governance concerns.
#YonhapInfomax #PharmaResearch #Pixelity #TunnelingAllegations #ShareholderOpposition #RevenueDependence #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=70849
PharmaResearch Addresses Tunneling Allegations—'Transactions with Pixelity Were Fair'

PharmaResearch Co. has denied tunneling allegations in its dealings with Pixelity, asserting that all transactions were fair and market-based, but investor skepticism persists amid ongoing governance concerns.

Yonhap Infomax
Yonhap Infomax NewsJun 30, 2025
CVC Capital Partners faces mounting pressure to clarify its stance on PharmaResearch’s spin-off, as Must Asset Management demands answers over governance and succession concerns, with key conversion and redemption rights at stake.
#YonhapInfomax #CvcCapitalPartners #PharmaResearch #SpinOff #MustAssetManagement #RedemptionRights #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=69964
Will CVC Break Its Silence on PharmaResearch Split—Must Asset Management Sets Response Deadline D-1

CVC Capital Partners faces mounting pressure to clarify its stance on PharmaResearch’s spin-off, as Must Asset Management demands answers over governance and succession concerns, with key conversion and redemption rights at stake.

Yonhap Infomax
Yonhap Infomax NewsJun 25, 2025
PharmaResearch’s restructuring plan, echoing Google’s 2015 move, sparked a 17% share price drop as investors questioned dual listing and shareholder motives.
#YonhapInfomax #PharmaResearch #Google #HoldingCompany #DualListing #SharePriceDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=69187
[From the Field]Google in 2015, PharmaResearch in 2025

PharmaResearch’s restructuring plan, echoing Google’s 2015 move, sparked a 17% share price drop as investors questioned dual listing and shareholder motives.

Yonhap Infomax
Yonhap Infomax NewsJun 24, 2025
Must Asset Management has publicly challenged PharmaResearch’s planned holding company spin-off, questioning its governance rationale and urging transparency on shareholder interests.
#YonhapInfomax #MustAssetManagement #PharmaResearch #SpinOff #CorporateGovernance #ShareholderInterests #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=69072
Must Asset Management Questions PharmaResearch's Rationale for Spin-Off, Seeks Clarity on Governance Benefits Over Non-Redundant Physical Split

Must Asset Management has publicly challenged PharmaResearch’s planned holding company spin-off, questioning its governance rationale and urging transparency on shareholder interests.

Yonhap Infomax
Yonhap Infomax NewsJun 23, 2025
PharmaResearch Co. defended its spin-off plan, stating the split ratio was set through expert review to minimize tax and legal risks, while pledging equal shareholder rights and transparency amid market concerns over governance and valuation.
#YonhapInfomax #PharmaResearch #SpinOff #ShareholderRights #TaxRisks #MarketCapitalization #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=68782
Yonhap Infomax NewsJun 16, 2025
Must Asset Management has publicly opposed PharmaResearch's planned equity spin-off, warning it primarily benefits major shareholders and could worsen corporate governance, as shares plunged 17% and market cap fell by 1 trillion won ($725 million).
#YonhapInfomax #PharmaResearch #MustAssetManagement #EquitySpinOff #ShareholderGovernance #MarketCapitalizationDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67665
[PharmaResearch Spin-off③] Must Asset Management - 'A Decision Favoring Only Major Shareholders'

Must Asset Management has publicly opposed PharmaResearch's planned equity spin-off, warning it primarily benefits major shareholders and could worsen corporate governance, as shares plunged 17% and market cap fell by 1 trillion won ($725 million).

Yonhap Infomax
Yonhap Infomax NewsJun 13, 2025
South Korea's KOSPI index fell below the 2,900 mark after just two days as Israel's airstrikes on Iran triggered risk-off sentiment, with institutional selling outweighing foreign and retail buying; KOSDAQ also slumped, led by a sharp drop in PharmaResearch shares following a spin-off announcement.
#YonhapInfomax #KOSPI #IsraelAirstrikes #PharmaResearch #InstitutionalSelling #WTICrudeFutures #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=67469
Investor Sentiment Sours on Israel Airstrikes—KOSPI Surrenders 2,900 Mark After Two Days

South Korea's KOSPI index fell below the 2,900 mark after just two days as Israel's airstrikes on Iran triggered risk-off sentiment, with institutional selling outweighing foreign and retail buying; KOSDAQ also slumped, led by a sharp drop in PharmaResearch shares following a spin-off announcement.

Yonhap Infomax